Profile: Urologix, Inc., develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. We develop and offer non-surgical, catheter-based treatments that use proprietary microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Our treatment for enlarged prostate has proven to be effective with more than 225,000 patients treated to date. Our patented Cooled ThermoTherapy™ technology is an effective treatment options for a wide range of patients with BPH. Our Cooled ThermoTherapy enlarged prostate treatments deliver precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue & enhance the patient's comfort. Our Targis® System is comprised of a control unit called CoolWave® control unit, a microwave catheter, a rectal thermal sensing unit (RTU) and a coolant bag. Our Targis® system uses cooled thermotherapy to deliver precisely targeted microwave energy deep into hyperplastic prostate tissue creating coagulative necrosis for durable1 clinical outcomes.

The company was founded in 1991, has revenues of USD 10-25 Million, has ~80 employees and is ISO 9001, CE certified. NASDAQ:ULGX (SEC Filings)

FDA Registration Number: 2133936